Guardant Health
About Guardant Health
Guardant Health is a leading precision oncology company dedicated to transforming cancer care through innovative blood and tissue tests, real-world data, and advanced AI analytics. The company’s mission is to provide critical insights that empower physicians to make more informed decisions across the entire cancer care continuum, ultimately aiming to give every person more time free from cancer.
For physicians, Guardant Health offers a comprehensive suite of products designed to address various stages of cancer management. This includes tests like Guardant360® CDx for comprehensive genomic profiling in advanced solid tumor cancers, aiding in treatment selection and monitoring response to therapy. Guardant Reveal™ is utilized for molecular residual disease (MRD) detection and recurrence monitoring in early-stage colorectal, breast, and lung cancers following curative-intent therapy. Additionally, the Shield™ blood test, which received FDA approval, provides a less invasive option for colorectal cancer screening in average-risk, asymptomatic adults, aiming to increase screening rates and detect cancer earlier.
Guardant Health’s approach leverages the power of liquid biopsies, which can overcome limitations of traditional tissue biopsies such as invasiveness, potential delays, and insufficient tissue availability. By analyzing circulating tumor DNA (ctDNA) from a simple blood draw, their tests provide a more complete genomic picture, enabling earlier intervention, guiding treatment adjustments, and accelerating drug development for the next generation of precision medicines.
Focus Areas
Business Intelligence
| Key Investors | Lightspeed Venture Partners, Sequoia Capital, SoftBank Vision Fund, OrbiMed, Khosla Ventures, 8VC |
| Partnerships | Merck (companion diagnostics and cancer therapies) [cite: 3 (from previous search)], Trial Library (cancer clinical trial access) [cite: 18 (from previous search)], Zephyr AI (drug response predictions and biomarker insights) [cite: 20 (from previous search)], PathGroup (Shield blood test distribution) [cite: 22 (from previous search)], American Cancer Society (cancer screening access and health equity) [cite: 25 (from previous search)], Quest Diagnostics (Shield blood test distribution) [cite: 28 (from previous search)], Pfizer (new cancer therapies using Guardant Infinity Smart Liquid Biopsy Platform) [cite: 27 (from previous search)], Adicon Holdings Limited (Guardant tests for clinical trials in China) [cite: 27 (from previous search)] |
| Acquisitions | MetaSight Diagnostics (Feb 2026) [cite: 9 (from previous search), 15 (from previous search), 26 (from previous search), 30 (from previous search), 41 (from previous search)], Guardant Health AMEA (Jun 2022) [cite: 1 (from previous search), 11 (from previous search), 15 (from previous search), 29 (from previous search)], Bellwether Bio (Mar 2019) [cite: 15 (from previous search)] |
| Technology | Guardant Infinity™ Smart platform, liquid biopsy technology, advanced analytics, AI analytics, Digital Sequencing™ |
| FDA Clearances | 2+ cleared products (estimated) |
What Physicians Need to Know
For physicians, Guardant Health's tests offer several advantages: nn* **Actionable Insights:** Rapid and comprehensive genomic and epigenomic profiling from a simple blood draw provides actionable information for therapy selection, even when tissue is limited or difficult to obtain.n* **Overcoming Tissue Biopsy Limitations:** Liquid biopsies reduce the need for invasive tissue biopsies, minimize delays in treatment, and can capture tumor heterogeneity and evolving mutations more effectively.n* **Early Detection & Monitoring:** The Shieldu2122 test provides a convenient screening option for colorectal cancer, potentially increasing adherence. Guardant Revealu00ae enables earlier detection of molecular residual disease and recurrence, allowing for timely intervention.n* **Comprehensive Patient Management:** The Guardant Completeu00ae portfolio supports patient care across screening, early-stage, and advanced cancer, offering a holistic view of the disease.n* **Access to Clinical Trials:** Partnerships and AI-powered platforms (like InfinityAI and collaboration with Trial Library) can help identify eligible patients for precision oncology clinical trials, broadening access to novel therapies.n* **Broad Coverage:** Many Guardant tests are broadly covered by Medicare and major private insurers, ensuring accessibility for a large patient population.
Guardant Health actively integrates its technologies and data through strategic collaborations. They partner with biopharmaceutical companies (e.g., Merck, Boehringer Ingelheim, AstraZeneca, Janssen, Amgen, Daiichi Sankyo) for companion diagnostic development, clinical trial enrollment, and accelerating new cancer therapies. Their real-world data and AI analytics, powered by InfinityAI, are utilized in partnerships with companies like COTA and Zephyr AI to advance precision oncology research, biomarker discovery, and drug response predictions. Furthermore, collaborations with organizations like Trial Library aim to enhance patient access to cancer clinical trials by integrating genomic insights with AI-powered matching platforms.
What the Web Says
Guardant Health is a biotechnology company specializing in liquid biopsy tests for cancer detection and treatment guidance. Their products, such as Guardant360 and Guardant Reveal, are generally well-regarded by patients and some healthcare professionals for their utility in guiding treatment decisions and providing insights into cancer mutations. However, employer reviews indicate a mixed to negative sentiment regarding work-life balance, management, and company culture, with some employees praising benefits and coworkers while others report high stress and disorganization.
Overall: MixedStrengths
- Products like Guardant360 are helpful in guiding cancer treatment and identifying mutations.
- Tests can provide critical insights into disease drivers through advanced blood and tissue tests.
- Good benefits and pay are often cited by employees.
- Some employees find their immediate teams and coworkers to be superb.
- The company's mission to conquer cancer with data is seen as ambitious and impactful.
- Guardant Health tests like Shield for colorectal cancer screening have shown high sensitivity and specificity.
Limitations
- Poor work-life balance and long hours are frequently mentioned by employees.
- Management is often described as disorganized, setting unrealistic goals, and lacking support.
- Company culture can be toxic, with issues of nepotism, favoritism, and a lack of concern for employee well-being.
- Concerns about job security and recent layoffs have been raised.
- Some patients have experienced issues with insurance coverage and unexpected high costs for tests.
- Technical difficulties and delays in accessing test results on the patient portal have been reported.
Based on reviews from: Indeed.com, SimplyHired, Comparably, Reddit, Colorectal Cancer Alliance, Wikipedia, Reuters, YouTube
Last updated: 2026-07-22
Videos
News, demos, and interviews about Guardant Health.
Videos load interactively. If none appear, search YouTube for Guardant Health →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded Guardant Health.
Related Companies
Google DeepMind is a leading artificial intelligence (AI) research laboratory, a subsidiary of Alphabet Inc., dedicated to developing advanced AI systems to benefit humanity. The company focuses on creating general-purpose AI that can learn and solve complex problems, drawing inspiration from neuroscience and machine learning. Their work spans various fields, including healthcare, scientific discovery, and […]
TalkToMedi is a Canadian healthcare AI company that has developed a clinical-grade voice AI platform called MEDI. This platform is designed to automate patient communication and administrative tasks for medical clinics, including family medicine, specialty clinics, allied health, and physiotherapy. MEDI handles high-volume patient calls, automating appointment inquiries, booking, rescheduling, and cancellations based on the […]
Menaela is an AI-first practice management system designed for solo practitioners, small private clinics, and clinic owners. It integrates patient communication, scheduling, CRM, and medical documentation into a single platform, aiming to replace multiple disconnected tools and bots. The system features an AI practice manager that understands natural-language requests, utilizes real clinic data, and performs […]
Avie is operated by AVIE TECNOLOGIA LTDA, headquartered in Santo André, São Paulo, Brazil. Avie provides WhatsApp reception in Brazilian Portuguese, appointment scheduling, rescheduling and cancellations through Google Calendar or Feegow, clinic CRM, follow-up messages and an online booking website. Clinic staff can review conversations and take over when human support is needed. Clinic CRM […]
Saile is a physician-founded healthcare technology company that addresses critical inefficiencies in healthcare staffing and credentialing. Their AI-powered platform acts as a “universal credential passport” for physicians, centralizing and managing all medical licenses, certifications, and CME credits in one secure, portable vault. This system aims to significantly reduce the administrative burden and delays associated with […]
Data Capture Experts (DCE) is an Australian-based healthcare AI company that is at the forefront of digital health transformation. They specialize in developing and implementing digital health platforms that integrate data, technology, and human-centered design to create intuitive and connected healthcare systems. Their flagship platform, DC2Vue, is designed to go beyond traditional Electronic Medical Records […]